Common variable immune deficiency: case studies.

This article discusses 3 cases in which patients with CVID had some of these presenting issues and what hematology input was required. PMID: 31808912 [PubMed - in process]
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

Related Links:

ConclusionsBlocking the SIRP α-CD47 interaction via SIRPα, while similarly efficacious in vitro, differentiates ADU-1805 from CD47-targeting agents with respect to safety and absence of inhibition of T-cell activation. The data presented herein support further advancement of ADU-1805 towards clinical development.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Abstract PURPOSE: The histone deacetylase (HDAC) inhibitor romidepsin and the anthracycline liposomal doxorubicin (LD) have modest single-agent activity in cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). We investigated the safety and efficacy of the combination of these two agents in CTCL and PTCL. EXPERIMENTAL DESIGN: Using CTCL cell lines and primary CTCL tumor cells, we demonstrated synergistic anti-tumor activity with romidepsin plus doxorubicin. We then conducted a phase I dose-escalation study of the romidepsin/LD combination in relapsed/refractory CTCL and PTCL. The primary obj...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Conclusion: Leukemic phase ALK-negative ALCL often carries a complex karyotype and requires early intensive polychemotherapy. Use of anabolic steroids depletes the ability of defending lymphocytes to remove tumour producing cells.
Source: Annals of Medicine and Surgery - Category: General Medicine Source Type: research
CONCLUSION: In our series, the predominance of males, a higher frequency of immune thrombocytopenia than autoimmune hemolytic anemia, the resistance to usual treatments and the efficacy of specific chemotherapy were consistent with the literature. Unexpectedly, patients were young and with nodular sclerosis morphology (vs. mixed cellularity) in 3 of 4 cases. PMID: 31668883 [PubMed - as supplied by publisher]
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research
ConclusionsSevere hypercalcemia and aplastic anemia are potential paraneoplastic syndromes of adult T-type lymphoblastic lymphoma, with fatal short-term outcome.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
ConclusionsThis is the first study evaluating a PRMT5 inhibitor. Overall, AEs were common but manageable. Patients with multiple tumor types responded to therapy. Part 2 of the study is open for subjects with predefined solid tumors and non-Hodgkin ’s lymphoma.Clinical trial identificationNCT02783300.Legal entity responsible for the studyGlaxoSmithKline.FundingGlaxoSmithKline.DisclosureL.L. Siu: Advisory / Consultancy: Merck (compensated), Pfizer (compensated), Celgene (compensated), AstraZeneca/Medimmune (compensated), Morphosys (compensated), Roche (compensated), GeneSeeq (compensated), Loxo (compensated), Oncorus ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsMost TRAEs were mild or moderate in severity and manageable with dose modifications. CC-90010 had a long terminal half-life that enabled less frequent dosing and promising anticancer activity. Dose escalation is complete, and expansion in select advanced malignancies is ongoing. Table: 1075PDose Level:1 (n  = 7)2 (n = 7)3A (n = 4)3B (n = 6)3C (n = 6)4A (n = 7)4B (n = 7)4C (n = 7)5A (n = 6)5B (n = 6)5C (n = 6)Dose, mg1515253015404525305535Schedule, days on/off3/...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Risk stratification of multiple myeloma (MM) at diagnosis allows prognostication and drives therapeutic decisions and currently the International staging system (ISS) and the Revised International staging system (RISS) are routinely utilized. Increased red blood cell distribution width (RDW), anemia, and thrombocytopenia have been shown to predict worse progression-free (PFS) and overall survival (OS). We hypothesized that the hematopoietic indices including mean corpuscular volume (MCV), hemoglobin (Hgb), and platelet (Plt) count may reflect the impact of the tumor cells on the marrow microenvironment and examined its abi...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Conditions:   Acute Leukemia;   Severe Aplastic Anemia;   Non-hodgkin Lymphoma;   Hodgkin Lymphoma;   Kostmann;   Diamond Blackfan Anemia;   Amegakaryocytic Thrombocytopenia;   Sickle Cell Disease;   Beta-Thalassemia Intervention:   Drug: alpha beta depletion Sponsor:   Mitchell Cairo Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
High-dose chemotherapy (HDT) followed by autologous hematopoietic stem cell transplantation (ASCT) is widely used in patients with malignant lymphomas. In Europe over 8,000 ASCTs for lymphoma were performed out of a total of 40,000 transplants according to the European Bone Marrow Transplant (EBMT) activity survey in 2017. ASCT is considered the standard treatment for eligible patients failing to achieve remission after first line chemotherapy or patients with relapsed or refractory lymphomas, including classical Hodkin's lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma, as well as con...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Anemia | Cancer & Oncology | Education | Genetics | Hematology | Lymphoma | Study | Thrombocytopenia | Universities & Medical Training